RNA Drugs: Has the "Golden Narrative" Collapsed?
Time：
2026-09-03 08:51
Author：
At 27, AstraZeneca Has a Touch of Melancholy
Time：
2026-09-02 08:52
Author：
xieyijun
Sweeping, clearing, and discounting: The pricing paradox of innovative drugs in China
A billion-dollar BD cannot buy recognition in the secondary market
Time：
2026-08-31 08:02
Author：
xieyijun
Is the IPO going to change in Hong Kong?
Time：
2026-08-30 09:03
Author：
xieyijun
China Biotech 2026: America Against America(Part 3)
Time：
2026-08-29 14:15
Author：
Morgan Xu, PhD
Ivonescimab Scores Another "Head-to-Head" Victory
Only Challenging the "Strongest Comparator"
Time：
2026-08-28 18:17
Author：
xieyijun
China Biotech 2026: America Against America(Part 2)
Time：
2026-08-28 17:18
Author：
Morgan Xu, PhD
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务